{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T07:59:39Z","timestamp":1792828779616,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s00259-025-07624-1","type":"journal-article","created":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T03:21:19Z","timestamp":1761189679000},"page":"2325-2336","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["PET in myeloma redefined: a comparative imaging study with FDG and fluorocholine PET\/CT"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3157-5782","authenticated-orcid":false,"given":"Gursan","family":"Kaya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serkan","family":"Akin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yahya","family":"Buyukasik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murat Fani","family":"Bozkurt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murat","family":"Tuncel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinar Ozgen","family":"Kiratli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,23]]},"reference":[{"key":"7624_CR1","unstructured":"Malin Hultcrantz GJM, Landgren O, Dimopoulos TF. Evangelos Terpos editor: Springer; 2018."},{"issue":"1","key":"7624_CR2","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s00428-022-03431-3","volume":"482","author":"F Fend","year":"2023","unstructured":"Fend F, Dogan A, Cook JR. Plasma cell neoplasms and related entities-evolution in diagnosis and classification. Virchows Arch. 2023;482(1):163\u201377.","journal-title":"Virchows Arch"},{"issue":"12","key":"7624_CR3","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.6004\/jnccn.2023.0061","volume":"21","author":"SK Kumar","year":"2023","unstructured":"Kumar SK, Callander NS, Adekola K, Anderson LD Jr., Baljevic M, Baz R, et al. Multiple myeloma, version 2.2024, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2023;21(12):1281\u2013301.","journal-title":"J Natl Compr Canc Netw"},{"issue":"5","key":"7624_CR4","doi-asserted-by":"publisher","first-page":"e367","DOI":"10.1016\/S2352-3026(23)00030-3","volume":"10","author":"C Nanni","year":"2023","unstructured":"Nanni C, Kobe C, Bae\u00dfler B, Baues C, Boellaard R, Borchmann P, et al. European association of nuclear medicine (EANM) focus 4 consensus recommendations: molecular imaging and therapy in haematological tumours. Lancet Haematol. 2023;10(5):e367\u201381.","journal-title":"Lancet Haematol"},{"issue":"8","key":"7624_CR5","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1002\/ajh.26590","volume":"97","author":"SV Rajkumar","year":"2022","unstructured":"Rajkumar SV. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol. 2022;97(8):1086\u2013107.","journal-title":"Am J Hematol"},{"key":"7624_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.825394","volume":"12","author":"A Guha","year":"2022","unstructured":"Guha A, Vijan A, Agarwal U, Goda JS, Mahajan A, Shetty N, et al. Imaging for plasma cell dyscrasias: what, when, and how? Front Oncol. 2022;12:825394.","journal-title":"Front Oncol"},{"issue":"1","key":"7624_CR7","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1182\/blood-2017-03-774422","volume":"130","author":"L Rasche","year":"2017","unstructured":"Rasche L, Angtuaco E, McDonald JE, Buros A, Stein C, Pawlyn C, et al. Low expression of hexokinase-2 is associated with false-negative FDG\u2013positron emission tomography in multiple myeloma. Blood. 2017;130(1):30\u20134.","journal-title":"Blood"},{"issue":"6","key":"7624_CR8","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1007\/s00259-019-04312-9","volume":"46","author":"Y Abe","year":"2019","unstructured":"Abe Y, Ikeda S, Kitadate A, Narita K, Kobayashi H, Miura D, et al. Low hexokinase-2 expression-associated false-negative 18F-FDG PET\/CT as a potential prognostic predictor in patients with multiple myeloma. Eur J Nucl Med Mol Imaging. 2019;46(6):1345\u201350.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7624_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13060911","author":"S Gokhale","year":"2021","unstructured":"Gokhale S, Xie P. ChoK-Full of potential: choline kinase in B cell and T cell malignancies. Pharmaceutics. 2021. https:\/\/doi.org\/10.3390\/pharmaceutics13060911.","journal-title":"Pharmaceutics"},{"key":"7624_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics13091570","author":"P Garrastachu Zumar\u00e1n","year":"2023","unstructured":"Garrastachu Zumar\u00e1n P, Garc\u00eda Meg\u00edas I, Mangas Losada M, Mendoza Melero A, Villanueva Torres A, Boulvard Chollet X, et al. Multitracer PET\/CT with [(18)F]fluorodeoxiglucose and [(18)F]fluorocholine in the initial staging of multiple myeloma patients applying the impetus criteria: a pilot study. Diagnostics. 2023. https:\/\/doi.org\/10.3390\/diagnostics13091570.","journal-title":"Diagnostics"},{"issue":"11","key":"7624_CR11","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1007\/s00259-016-3392-7","volume":"43","author":"T Cassou-Mounat","year":"2016","unstructured":"Cassou-Mounat T, Balogova S, Nataf V, Calzada M, Huchet V, Kerrou K, et al. 18F-fluorocholine versus 18F-fluorodeoxyglucose for PET\/CT imaging in patients with suspected relapsing or progressive multiple myeloma: a pilot study. Eur J Nucl Med Mol Imaging. 2016;43(11):1995\u20132004.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7624_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7819-5-68","volume":"5","author":"C Nanni","year":"2007","unstructured":"Nanni C, Zamagni E, Cavo M, Rubello D, Tacchetti P, Pettinato C, et al. 11 C-choline vs. 18F-FDG PET\/CT in assessing bone involvement in patients with multiple myeloma. World J Surg Oncol. 2007;5:68.","journal-title":"World J Surg Oncol"},{"issue":"8","key":"7624_CR13","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1097\/RLU.0000000000002638","volume":"44","author":"C Lapa","year":"2019","unstructured":"Lapa C, Kircher M, Da Via M, Schreder M, Rasche L, Kort\u00fcm KM, et al. Comparison of 11 C-choline and 11 C-methionine PET\/CT in multiple myeloma. Clin Nucl Med. 2019;44(8):620\u20134.","journal-title":"Clin Nucl Med"},{"issue":"5","key":"7624_CR14","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1007\/s00259-017-3909-8","volume":"45","author":"C Nanni","year":"2018","unstructured":"Nanni C, Versari A, Chauvie S, Bertone E, Bianchi A, Rensi M, et al. Interpretation criteria for FDG PET\/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (italian myeloma criteria for PET use). Eur J Nucl Med Mol Imaging. 2018;45(5):712\u20139.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"7624_CR15","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1007\/s00259-017-3829-7","volume":"45","author":"R Ladenstein","year":"2018","unstructured":"Ladenstein R, Lambert B, P\u00f6tschger U, Castellani MR, Lewington V, Bar-Sever Z, et al. Validation of the mIBG skeletal SIOPEN scoring method in two independent high-risk neuroblastoma populations: the SIOPEN\/HR-NBL1 and COG-A3973 trials. Eur J Nucl Med Mol Imaging. 2018;45(2):292\u2013305.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"7624_CR16","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.7150\/thno.18068","volume":"7","author":"DL Chan","year":"2017","unstructured":"Chan DL, Pavlakis N, Schembri GP, Bernard EJ, Hsiao E, Hayes A, et al. Dual somatostatin receptor\/FDG PET\/CT imaging in metastatic neuroendocrine tumours: proposal for a novel grading scheme with prognostic significance. Theranostics. 2017;7(5):1149\u201358.","journal-title":"Theranostics"},{"key":"7624_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/life13030611","author":"F Dondi","year":"2023","unstructured":"Dondi F, Lazzarato A, Gorica J, Guglielmo P, Borgia F, Filice R, et al. PET criteria by cancer type from imaging interpretation to treatment response assessment: beyond FDG PET score. Life (Basel). 2023. https:\/\/doi.org\/10.3390\/life13030611.","journal-title":"Life (Basel)"},{"issue":"4","key":"7624_CR18","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.2214\/ajr.184.4.01841199","volume":"184","author":"MA Bredella","year":"2005","unstructured":"Bredella MA, Steinbach L, Caputo G, Segall G, Hawkins R. Value of FDG PET in the assessment of patients with multiple myeloma. AJR Am J Roentgenol. 2005;184(4):1199\u2013204.","journal-title":"AJR Am J Roentgenol"},{"issue":"3","key":"7624_CR19","doi-asserted-by":"publisher","first-page":"514","DOI":"10.2214\/AJR.18.20989","volume":"213","author":"J Chen","year":"2019","unstructured":"Chen J, Li C, Tian Y, Xiao Q, Deng M, Hu H, et al. Comparison of whole-body DWI and (18)F-FDG PET\/CT for detecting intramedullary and extramedullary lesions in multiple myeloma. AJR Am J Roentgenol. 2019;213(3):514\u201323.","journal-title":"AJR Am J Roentgenol"},{"issue":"1095","key":"7624_CR20","doi-asserted-by":"publisher","DOI":"10.1259\/bjr.20180768","volume":"92","author":"T Barwick","year":"2019","unstructured":"Barwick T, Bretsztajn L, Wallitt K, Amiras D, Rockall A, Messiou C. Imaging in myeloma with focus on advanced imaging techniques. Br J Radiol. 2019;92(1095):20180768.","journal-title":"Br J Radiol"},{"issue":"1","key":"7624_CR21","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s00259-024-06858-9","volume":"52","author":"C Nanni","year":"2024","unstructured":"Nanni C, Deroose CM, Balogova S, Lapa C, Withofs N, Subesinghe M, et al. EANM guidelines on the use of [(18)F]FDG PET\/CT in diagnosis, staging, prognostication, therapy assessment, and restaging of plasma cell disorders. Eur J Nucl Med Mol Imaging. 2024;52(1):171\u201392.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"7624_CR22","doi-asserted-by":"publisher","first-page":"3697","DOI":"10.1007\/s00259-023-06339-5","volume":"50","author":"C Sachpekidis","year":"2023","unstructured":"Sachpekidis C, Enqvist O, Ul\u00e9n J, Kopp-Schneider A, Pan L, Jauch A, et al. Application of an artificial intelligence-based tool in [(18)F]FDG PET\/CT for the assessment of bone marrow involvement in multiple myeloma. Eur J Nucl Med Mol Imaging. 2023;50(12):3697\u2013708.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"7624_CR23","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.mjafi.2023.08.007","volume":"79","author":"U Yanamandra","year":"2023","unstructured":"Yanamandra U, Reddy Gorla AK, Agrawal K, Mittal BR, Prakash G, Khadwal AR, et al. Prognostic significance of extramedullary disease (EMD) detected on pre-transplant (18)F-FDG PET\/CT in patients with multiple myeloma: results of PIPET-M trial. Med J Armed Forces India. 2023;79(6):672\u20138.","journal-title":"Med J Armed Forces India"},{"issue":"4","key":"7624_CR24","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/s41416-022-02061-5","volume":"128","author":"DL Chan","year":"2023","unstructured":"Chan DL, Hayes AR, Karfis I, Conner A, Furtado O\u2019Mahony L, Mileva M, et al. Dual [(68)Ga]DOTATATE and [(18)F]FDG PET\/CT in patients with metastatic gastroenteropancreatic neuroendocrine neoplasms: a multicentre validation of the NETPET score. Br J Cancer. 2023;128(4):549\u201355.","journal-title":"Br J Cancer"},{"key":"7624_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/medsci9010003","author":"SA Padala","year":"2021","unstructured":"Padala SA, Barsouk A, Barsouk A, Rawla P, Vakiti A, Kolhe R, et al. Epidemiology, staging, and management of multiple myeloma. Med Sci. 2021. https:\/\/doi.org\/10.3390\/medsci9010003.","journal-title":"Med Sci"},{"issue":"4","key":"7624_CR26","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1002\/jmri.27934","volume":"55","author":"M Sun","year":"2022","unstructured":"Sun M, Cheng J, Ren C, Zhang Y, Li Y, Wang L, et al. Differentiation of diffuse infiltration pattern in multiple myeloma from hyperplastic hematopoietic bone marrow: qualitative and quantitative analysis using whole-body MRI. J Magn Reson Imaging. 2022;55(4):1213\u201325.","journal-title":"J Magn Reson Imaging"},{"issue":"6","key":"7624_CR27","doi-asserted-by":"publisher","first-page":"e300","DOI":"10.1097\/RLU.0000000000000773","volume":"40","author":"C Sachpekidis","year":"2015","unstructured":"Sachpekidis C, Mai EK, Goldschmidt H, Hillengass J, Hose D, Pan L, et al. (18)F-FDG dynamic PET\/CT in patients with multiple myeloma: patterns of tracer uptake and correlation with bone marrow plasma cell infiltration rate. Clin Nucl Med. 2015;40(6):e300\u20137.","journal-title":"Clin Nucl Med"},{"issue":"3","key":"7624_CR28","first-page":"175","volume":"35","author":"A Cengiz","year":"2018","unstructured":"Cengiz A, Arda H, D\u00f6\u011fer F, Yava\u015fo\u011flu \u0130, Y\u00fcrekli Y, Bolaman AZ. Correlation between baseline 18F-FDG PET\/CT findings and CD38- and CD138-expressing myeloma cells in bone marrow and clinical parameters in patients with multiple myeloma. Turk J Haematol. 2018;35(3):175\u201380.","journal-title":"Turk J Haematol"},{"issue":"4","key":"7624_CR29","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.jgo.2021.12.004","volume":"13","author":"S Giri","year":"2022","unstructured":"Giri S, Dahal S, Bal S, Godby KN, Richman J, Olszewski AJ, et al. Pre-treatment neutrophil to lymphocyte ratio as a biomarker of frailty and predictor of survival among older adults with multiple myeloma. J Geriatr Oncol. 2022;13(4):486\u201392.","journal-title":"J Geriatr Oncol"},{"issue":"1","key":"7624_CR30","doi-asserted-by":"publisher","first-page":"21","DOI":"10.4065\/78.1.21","volume":"78","author":"RA Kyle","year":"2003","unstructured":"Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78(1):21\u201333.","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"7624_CR31","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s00259-019-04605-z","volume":"47","author":"Q Pan","year":"2020","unstructured":"Pan Q, Cao X, Luo Y, Li J, Feng J, Li F. Chemokine receptor-4 targeted PET\/CT with (68)Ga-Pentixafor in assessment of newly diagnosed multiple myeloma: comparison to (18)F-FDG PET\/CT. Eur J Nucl Med Mol Imaging. 2020;47(3):537\u201346.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"7624_CR32","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s00277-010-1037-7","volume":"90","author":"I Ak","year":"2011","unstructured":"Ak I, Gulbas Z. F-18 FDG uptake of bone marrow on PET\/CT scan: it\u2019s correlation with CD38\/CD138 expressing myeloma cells in bone marrow of patients with multiple myeloma. Ann Hematol. 2011;90(1):81\u20137.","journal-title":"Ann Hematol"},{"issue":"12","key":"7624_CR33","doi-asserted-by":"publisher","first-page":"3254","DOI":"10.1158\/1078-0432.CCR-13-2910","volume":"20","author":"G Fouquet","year":"2014","unstructured":"Fouquet G, Guidez S, Van de Herbaux C, Bonnet S, Beauvais D, et al. Impact of initial FDG-PET\/CT and serum-free light chain on transformation of conventionally defined solitary plasmacytoma to multiple myeloma. Clin Cancer Res. 2014;20(12):3254\u201360.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"7624_CR34","doi-asserted-by":"publisher","first-page":"205","DOI":"10.7150\/thno.16576","volume":"7","author":"C Lapa","year":"2017","unstructured":"Lapa C, Schreder M, Schirbel A, Samnick S, Kort\u00fcm KM, Herrmann K, et al. [(68)Ga]Pentixafor-PET\/CT for imaging of chemokine receptor CXCR4 expression in multiple myeloma - comparison to [(18)F]FDG and laboratory values. Theranostics. 2017;7(1):205\u201312.","journal-title":"Theranostics"},{"key":"7624_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12041042","author":"MI Morales-Lozano","year":"2020","unstructured":"Morales-Lozano MI, Viering O, Samnick S, Rodriguez-Otero P, Buck AK, Marcos-Jubilar M, et al. (18)F-FDG and (11)C-Methionine PET\/CT in newly diagnosed multiple myeloma patients: comparison of volume-based PET biomarkers. Cancers (Basel). 2020. https:\/\/doi.org\/10.3390\/cancers12041042.","journal-title":"Cancers (Basel)"},{"issue":"4","key":"7624_CR36","first-page":"418","volume":"56","author":"T Inoue","year":"2015","unstructured":"Inoue T, Nagai K, Momoi A, Isahai N, Sakai T, Sekiya M. [Efficacy of serum Immunoglobulin free light chain and 18F-FDG PET\/CT for therapeutic evaluation in a case with multiple plasmacytoma of bone]. Rinsho Ketsueki. 2015;56(4):418\u201322.","journal-title":"Rinsho Ketsueki"},{"issue":"9","key":"7624_CR37","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1038\/s41409-023-02017-0","volume":"58","author":"A Mookerjee","year":"2023","unstructured":"Mookerjee A, Gupta R, Kumar R, Sharma A, Pandey RM, Kumar L. Dual assessment with multiparameter flow cytometry and (18)F-FDG PET\/CT scan provides enhanced prediction of measurable residual disease after autologous haemopoietic stem cell transplant in myeloma-a prospective study. Bone Marrow Transplant. 2023;58(9):1045\u20137.","journal-title":"Bone Marrow Transplant"},{"key":"7624_CR38","doi-asserted-by":"publisher","first-page":"102017","DOI":"10.1016\/j.eclinm.2023.102017","volume":"60","author":"E Zamagni","year":"2023","unstructured":"Zamagni E, Oliva S, Gay F, Capra A, Rota-Scalabrini D, D\u2019Agostino M, et al. Impact of minimal residual disease standardised assessment by FDG-PET\/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub-study of the FORTE trial. EClinicalMedicine. 2023;60:102017.","journal-title":"EClinicalMedicine"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07624-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07624-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07624-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T05:38:48Z","timestamp":1771479528000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07624-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,23]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["7624"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07624-1","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,23]]},"assertion":[{"value":"19 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}}]}}